BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 3129809)

  • 1. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states.
    Kruithof EK; Gudinchet A; Bachmann F
    Thromb Haemost; 1988 Feb; 59(1):7-12. PubMed ID: 3129809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis.
    Tran-Thang C; Fasel-Felley J; Pralong G; Hofstetter JR; Bachmann F; Kruithof EK
    Thromb Haemost; 1989 Sep; 62(2):651-3. PubMed ID: 2510345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activator inhibitors type 1 and type 2 and plasminogen activators in amniotic fluid during pregnancy.
    Estellés A; Gilabert J; Andrés C; España F; Aznar J
    Thromb Haemost; 1990 Oct; 64(2):281-5. PubMed ID: 2125378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression by U-937 mononuclear phagocytes. Effects of 1 alpha, 25-dihydroxyvitamin D3 and phorbol ester.
    Gyetko MR; Webb AC; Sitrin RG
    J Immunol; 1988 Oct; 141(8):2693-8. PubMed ID: 3139763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasminogen activator inhibitor activity in bacterial infection.
    Páramo JA; Fernández Diaz FJ; Rocha E
    Thromb Haemost; 1988 Jun; 59(3):451-4. PubMed ID: 3142082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction.
    Huber K; Rosc D; Resch I; Schuster E; Glogar DH; Kaindl F; Binder BR
    Thromb Haemost; 1988 Dec; 60(3):372-6. PubMed ID: 3149044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.
    Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F
    Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease.
    Oseroff A; Krishnamurti C; Hassett A; Tang D; Alving B
    J Lab Clin Med; 1989 Jan; 113(1):88-93. PubMed ID: 2783330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased plasminogen activator inhibition levels in malignancy.
    de Jong E; Knot EA; Piket D; Iburg AH; Rijken DC; Veenhof KH; Dooijewaard G; ten Cate JW
    Thromb Haemost; 1987 Apr; 57(2):140-3. PubMed ID: 3110994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1).
    Kluft C; Jie AF; Rijken DC; Verheijen JH
    Thromb Haemost; 1988 Apr; 59(2):329-32. PubMed ID: 3133814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
    Siegbahn A; Ruusuvaara L
    Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
    Hofmann R; Lehmer A; Buresch M; Hartung R; Ulm K
    Cancer; 1996 Aug; 78(3):487-92. PubMed ID: 8697395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients--relationship with plasma insulin.
    Juhan-Vague I; Roul C; Alessi MC; Ardissone JP; Heim M; Vague P
    Thromb Haemost; 1989 Jun; 61(3):370-3. PubMed ID: 2678583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levels of fibrinolytic activators and inhibitors in plasma after severe trauma.
    Sørensen JV
    Blood Coagul Fibrinolysis; 1994 Feb; 5(1):43-9. PubMed ID: 7514044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diurnal variation of the fibrinolytic system.
    Grimaudo V; Hauert J; Bachmann F; Kruithof EK
    Thromb Haemost; 1988 Jun; 59(3):495-9. PubMed ID: 3142085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
    van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
    Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
    Allan EH; Martin TJ
    J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors.
    Landau BJ; Kwaan HC; Verrusio EN; Brem SS
    Cancer Res; 1994 Feb; 54(4):1105-8. PubMed ID: 8313368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A plasminogen activator inhibitor (PAI-2) circulates in two molecular forms during pregnancy.
    Booth NA; Reith A; Bennett B
    Thromb Haemost; 1988 Feb; 59(1):77-9. PubMed ID: 3129811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.